IMDX
Insight Molecular Diagnostics Inc.
There isn't enough reported data to score IMDX yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
IMDX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
IMDX's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
IMDX PE Valuation
IMDX has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
IMDX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IMDX's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
IMDX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.52 | +$2.21 |
| Q1 2026 | -$1.51 | +$2.28 |
| Q4 2025 | -$1.65 | +$3.01 |
| Q3 2025 | -$3.09 | +$1.27 |
| Q2 2025 | -$3.73 | +$0.46 |
| Q1 2025 | -$3.79 | +$1.11 |
| Q4 2024 | -$4.66 | -$1.29 |
| Q3 2024 | -$4.36 | +$4.76 |
IMDX is still losing money, but far less than before: $1.52 per share over the past year, against $15.60 at its worst in early 2022.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over IMDX on earnings quality, reporting a profit while its opponent remains loss making.
IMDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $239K | -54% |
| Q1 2026 | $32K | -99% |
| Q4 2025 | $1.1M | -23% |
| Q3 2025 | $260K | +126% |
| Q2 2025 | $518K | +398% |
| Q1 2025 | $2.1M | +1115% |
| Q4 2024 | $1.5M | +373% |
| Q3 2024 | $115K | -73% |
IMDX's revenue has slid since its 2021 peak: $239,000 last quarter, down 54% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -4771% | -2871 points |
| Q1 2026 | -13791% | -13473 points |
| Q4 2025 | -2058% | +205 points |
| Q3 2025 | -4249% | +7503 points |
| Q2 2025 | -1900% | +2554 points |
| Q1 2025 | -318% | +4947 points |
| Q4 2024 | -2263% | +2890 points |
| Q3 2024 | -11752% | -10234 points |
IMDX's operating margin was −4771% last quarter, down 2871 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over IMDX on profitability, with a higher operating margin.
IMDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$10M | -$3.4M |
| Q1 2026 | -$8.3M | -$2.1M |
| Q4 2025 | -$7M | -$1.5M |
| Q3 2025 | -$5.6M | +$86K |
| Q2 2025 | -$6.6M | -$459K |
| Q1 2025 | -$6.2M | -$2.3M |
| Q4 2024 | -$5.6M | -$742K |
| Q4 2023 | -$4.8M | +$5.6M |
IMDX has burned cash in almost every quarter: −$31M over the past year, against −$24M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over IMDX on cash generation, producing positive trailing cash flow while its opponent burns cash.
IMDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.5% | +2.2M shares |
| 1 year | +15% | +4.7M shares |
| 3 years | +520% | +30.8M shares |
IMDX has 37M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over IMDX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
IMDX Net Leverage
IMDX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
IMDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.9 | Oversold |
| Stochastic | 5.8 | Oversold |
IMDX's weekly RSI is 28 (oversold) and its Stochastic is 6 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
IMDX PE vs Healthcare Sector
IMDX has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
IMDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.04 | 24% below |
| 20 week MA | $3.96 | 42% below |
| 50 week MA | $4.85 | 52% below |
| 100 week MA | $4.09 | 44% below |
| 200 week MA | $3.95 | 42% below |
IMDX is in a downtrend: it's below all five of its weekly moving averages, and 42% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over IMDX on trend strength, trading above more of its moving averages.
IMDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $42.4 | $47.0 | +11% |
| 2021 | $47.0 | $46.0 | -2.1% |
| 2022 | $46.0 | $7.60 | -83% |
| 2023 | $7.60 | $2.50 | -67% |
| 2024 | $2.50 | $2.11 | -16% |
| 2025 | $2.11 | $6.37 | +202% |
| 2026 YTD | $6.37 | $2.31 | -64% |
IMDX's yearly returns have swung widely, from +202% in 2025 to −83% in 2022. It's down 64% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over IMDX on returns for 2026, with the stronger performance.